noxetib 10 mg tabletta
goodwill pharma kft. - ezetimibe -
ezetimibe valeant 10 mg tabletta
pharmaswiss ceska republika s.r.o - ezetimibe -
ibuprofen lysine innfarm 342 mg filmtabletta
goodwill pharma kft. - ibuprofen lizin -
ezetimibe/simvastatin mylan 10 mg/10 mg tabletta
mylan ireland ltd. - ezetimibe; szimvasztatin -
ezetimibe/simvastatin mylan 10 mg/20 mg tabletta
mylan ireland ltd. - ezetimibe; szimvasztatin -
ezetimibe/simvastatin mylan 10 mg/40 mg tabletta
mylan ireland ltd. - ezetimibe; szimvasztatin -
mektovi
pierre fabre medicament - binimetinib - melanóma - daganatellenes szerek - binimetinib kombinálva encorafenib kezelésére javallt felnőtt betegek inoperábilis vagy áttétes melanoma a braf mutáció v600.
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - szelektív immunszuppresszánsok - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
ezetimibe/atorvastatin sandoz 10 mg/10 mg filmtabletta
sandoz hungária kft. - ezetimibe; atorvasztatin -
ezetimibe/atorvastatin sandoz 10 mg/20 mg filmtabletta
sandoz hungária kft. - ezetimibe; atorvasztatin -